Parasol Therapeutics Nets New Venture Capital Financing
Friday, April 24, 2009 5:50:00 AM PDT | VentureDeal Staff
Waltham, Massachusetts -- Pharmaceutical company Parasol Therapeutics has garnered $3.25 million in a new round of venture capital funding.
Parasol is a stealth stage company involved in pharmaceutical drug research and development.
Investors in the round included Polaris Venture Partners, Flagship Ventures and Lux Capital. Proceeds purposes from the financing were not disclosed.
Email Page | Print Page